Pressing Issues in Progressive MS: Experts Convene is organized by Vindico Medical Education.
Release Date: 3/28/2018
Expiration Date: 3/27/2020
The intended audience for this activity is neurologists and other health care professionals involved in the treatment of patients with progressive MS.
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative disorder of the central nervous system that represents the most common cause of nontraumatic neurological disability in young adults. Approximately 10% to 15% of patients with MS have primary progressive MS (PPMS), which, from onset, involves unremitting disease progression, without distinct relapses. Advances in the understanding of the pathogenesis of PPMS have resulted in the development of improved therapeutic approaches. In 2017, ocrelizumab became the first therapy to receive US Food and Drug Administration approval for the treatment of PPMS. Ocrelizumab’s status as the first drug approved for PPMS heralds a radical shift in the treatment paradigm for this disease. Rather than just managing symptoms, physicians now can modify the progressive course of the disease in many patients. In this CME activity, experts will evaluate recent evidence of the contribution of B cells to the pathogenesis of PPMS, as well as discuss how to incorporate new clinical data about B-cell–depleting therapies for the treatment of patients with PPMS into clinical practice.
Upon successful completion of this educational activity, participants should be better able to:
• Evaluate recent evidence about the contribution of B cells to the pathogenesis of progressive MS.
• Incorporate new clinical study findings about B-cell-depleting therapies for the treatment of patients with PPMS.
• Apply clinical data to determine the optimum candidates for monoclonal antibody therapy, and how to monitor treatment response.
• Address safety concerns related to the use of anti-CD20 B-cell-depleting therapies for PPMS and how to counsel patients regarding these issues.